The project, which launched in January this year, will use Isogenica's CIS display techniques combined with high-throughput sequencing to screen hundreds of trillions of peptides and to identify up to 100,000 peptide hits against target proteins.
Peptides have strong potential in identifying potential compounds for therapeutic and diagnostics drug discovery, which this project will attempt to improve.
Kevin Matthews, CEO, Isogenica, said: "The consortium partners are committed to improving the efficiency of peptide lead discovery and we believe this project brings that goal one step nearer."
Isogenica's consortium partners are Apogenix GmbH, Biametrics GmbH, Center for Advanced Bioanalysis, German Cancer Research Centre, Karlsruher Institute for Technology (KIT), Microsystems LTD, PEPperPRINT, Technical University of Varna, The MRC Weatherall Institute of Molecular Medicine (University of Oxford).
blog comments powered by Disqus